Form 4: Beam Therapeutics' Chief Medical Officer, Amy Simon, Reports Acquisition of 27,500 Shares of Common Stock

Amy Simon, Chief Medical Officer of Beam Therapeutics, reports acquiring 27,500 shares of common stock through restricted stock units.

Summary

• Amy Simon, the Chief Medical Officer of Beam Therapeutics Inc. (BEAM), filed a Form 4 on April 02, 2025, reporting a transaction that occurred on March 31, 2025.
• The transaction involved the acquisition of 27,500 shares of Beam Therapeutics' common stock.
• These shares were acquired through restricted stock units (RSUs) granted under the company's 2019 Equity Incentive Plan.
• The RSUs vest in four equal installments annually, contingent upon Simon's continued service with Beam Therapeutics.
• Following the reported transaction, Simon beneficially owns 96,305 shares of Beam Therapeutics' common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a key executive suggests confidence in the company's prospects. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The acquisition of shares by a key executive like the Chief Medical Officer can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continued service with BEAM through each vesting date.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the Chief Medical Officer's acquisition of company stock, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedule of the RSUs (four equal annual installments) is a fairly standard practice in the biotech industry.
• Comparing the size of the RSU grant to those of peer companies' executives would provide further context on the competitiveness of Beam Therapeutics' compensation practices.

Stakeholder Impact

• The acquisition of shares by a key executive can positively influence shareholder sentiment.

Key Dates

Keywords

Form 4, Beam Therapeutics, Amy Simon, Chief Medical Officer, Stock Acquisition, Restricted Stock Units, Equity Incentive Plan, Beneficial Ownership